SARS-CoV-2 vaccine (Intravacc/Epivax)

N/A

Report date: 2025/01/26 17:04:32

Base Information

Drug NameSARS-CoV-2 vaccine (Intravacc/Epivax)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlands
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntravacc BV
China Registration ClassN/A

Develop Information

Active CompaniesIntravacc BVEpiVax Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A